Effect of Corona Virus on Intravitreal Injections

Study Overview
=================
Brief Summary
-----------------
During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.

Detailed Description
-----------------
The corona virus pandemic may affects patients regular visits to ophthalmic clinic, we aim to study the sequel of the pandemic on intravitreal injections results in diabetic macular edema, wet age related macular degenerations, myopic choroidal new vascularization, and proliferative diabetic retinopathy.

Official Title
-----------------
Effects of Corona Virus Pandemic on Intravitreal Injections

Conditions
-----------------
Diabetic Macular Edema, Age-Related Macular Degeneration, Choroidal Neovascularization, Myopic Choroidal Neovascularisation, Diabetic Retinopathy

Intervention / Treatment
-----------------
* Drug: Anti-vascular endothelial growth factors (Anti-VEGFs)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with the following conditions (diabetic macular edema, wet age related macular degeneration, myopic choroidal new vascularization and retinal vein occlusion complicated with macular edema). Exclusion Criteria: patients that are known to have hypersensitivity to Anti-VEGFs.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Diabetic macular edema<br>Cases with diabetic macular edema that are prepared for intravitreal injection of anti-vascular endothelial growth factors. | Drug: Anti-vascular endothelial growth factors (Anti-VEGFs)<br>* Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).<br>|
| Active Comparator: Wet age related macular edema<br>Cases with wet age related macular degenerations that are prepared for intravitreal injection of anti-vascular endothelial growth factors. | Drug: Anti-vascular endothelial growth factors (Anti-VEGFs)<br>* Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).<br>|
| Active Comparator: Retinal vein occlusion<br>Cases with macular edema secondary to retinal vein occlusion that are prepared for intravitreal injection of anti-vascular endothelial growth factors. | Drug: Anti-vascular endothelial growth factors (Anti-VEGFs)<br>* Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).<br>|
| Active Comparator: Myopic choroidal new vascularization<br>Cases with myopic choroidal new vascularization that are prepared for intravitreal injection of anti-vascular endothelial growth factors. | Drug: Anti-vascular endothelial growth factors (Anti-VEGFs)<br>* Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity | Assessing the changes in best corrected visual acuity in logMAR unit measured by snellen chart. | Baseline and monthly after injection till one year of follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Central subfield thickness | Assessing the changes in central macular thickness in microns measured by optical coherence tomography | Baseline and monthly after injection till one year of follow-up |